Bildkälla: Stockfoto

Cantargia Q3 2022: Focus on Randomised Trials - Redeye

Redeye comments on Cantargia's third quarter report and events after the end of the quarter, including the decision to pause three trials.

Redeye comments on Cantargia's third quarter report and events after the end of the quarter, including the decision to pause three trials.
Börsvärldens nyhetsbrev
ANNONSER